You are here: Industry Insights > Bi

News List

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China PharmaSources
November 15, 2024
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China
Has the booming PD-1 inhibitor reached its limit? Krebs Qin
October 18, 2024
In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.
New Indication Approval for Ribociclib: A Game Changer for CDK4/6 Inhibitors Yefenghong
October 18, 2024
Recently, the FDA officially approved Novartis's ribociclib, in combination with aromatase inhibitors (AI), for the adjuvant treatment of hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC)
Decoding the Role of Synthetic Biology in Pharmaceuticals Neeta Ratanghayra
October 16, 2024
Recognized for its transformative potential, synthetic biology has emerged as a technology poised to revolutionize various industries, including pharmaceuticals.
Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization PharmaSources
October 15, 2024
Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today the appointment of Dr. Elisabeth Lackner to its Supervisory Board.
Inauguration of the New Richter BioLogics cGMP Facility for the Manufacture of Biopharmaceuticals for the Global Market PharmaSources
October 14, 2024
Richter BioLogics GmbH & Co KG, the microbial biologics affiliate of Gedeon Richter Plc. celebrated the opening of its new cutting-edge biopharmaceutical cGMP facility in Bovenau .
Antabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310 for Severe Hospital Infections PharmaSources
October 14, 2024
Antabio’s MEM-ANT3310 is a next generation broad-spectrum antibacterial combination that has been designed to address the growing problem of antimicrobial resistance in severe hospital infections.
Process Optimization and Cost Control of Targeted Drugs: Accelerating Innovation in Biopharmaceuticals David Orchard-Webb
September 03, 2024
In today's competitive drug development market, biopharmaceutical businesses are always under pressure to provide high-quality medicines swiftly and affordably.
Avantor Triumphs with Three Awards at Korea Biopharma Excellence Awards 2024 PharmaSources
August 26, 2024
Avantor, Inc. has secured three prestigious awards at the esteemed Korea Biopharma Excellence Awards (KBEA) 2024.
NEW OPTURA®PALM® Handheld Contactless Biomass Sensor from Aber Offers Accurate Cell Density Measurement in Seconds Without Sampling Biotech Newswire
August 09, 2024
Aber Instruments (Aber) is delighted to introduce its new OPTURA® PALM® handheld biomass sensor.